Publications by authors named "Tomohiro Oba"

Claim this Profile
A
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.
Tae Hata, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba

Clin Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early severe immune-related pneumonitis, hepatitis, and agranulocytosis with radiographic response in sarcomatoid malignant pleural mesothelioma treated with nivolumab and ipilimumab: a case report highlighting dual liver biopsies and rechallenge decision-making.
Tomohiro Oba, Katsuhiro Itogawa, Yoko Machida, Yuji Ono, Yuho Morita

Ther Adv Med Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paradoxical pericarditis in an immunocompetent patient with mediastinal tuberculous lymphadenitis and endobronchial TB: A case report.
Tomohiro Oba, Hidekazu Matsushima, Masako Amano, Keiichi Akasaka, Tomotaka Nishizawa

IDCases· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study.
Daiki Murata, Koichi Azuma, Kenta Murotani, Kazuhiro Ito, Takashi Nomizo, Tomohiro Oba

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.
Aosa Sasada, Hayato Kawachi, Tadaaki Yamada, Tae Hata, Yasuhiro Goto, Tomohiro Oba

Anticancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.
Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba

Int J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nutritional Status as a Risk Factor for the Early Discontinuation of Inhaled Liposomal Amikacin in Mycobacterium avium Complex Pulmonary Disease.
Hideaki Yamakawa, Chisa Uzuka, Daisuke Nakatani, Moe Nomaki, Tomohiro Oba

Cureus· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.
Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Tomohiro Oba

Cancer Res Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bronchial pleomorphic adenoma successfully diagnosed and resected with left lower sleeve lobectomy; a case report and literature review.
Katsuhiro Itogawa, Tomohiro Oba, Mitsuru Maki, Masako Amano, Akiko Adachi

Respir Med Case Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).
Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, Yuki Takeyasu, Yukihiro Hasegawa, Tomohiro Oba

Ther Adv Med Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study.
Ryo Sawada, Tadaaki Yamada, Yasuhiro Goto, Yoshiki Negi, Akira Nakao, Tomohiro Oba

Transl Lung Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study.
Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Tomohiro Oba

Clin Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.
Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba

Target Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression.
Hayato Kawachi, Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Tomohiro Oba

Transl Lung Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study.
Naoya Nishioka, Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Tomohiro Oba

Cancer Res Treat· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.
Shiho Goda, Tadaaki Yamada, Kenji Morimoto, Tae Hata, Yasuhiro Goto, Tomohiro Oba

Transl Lung Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba

Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients.
Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Tomohiro Oba

Lung Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility, safety, and clinical outcomes of modified laparoscopic cervicoisthmic cerclage for refractory cervical insufficiency: A single-arm clinical trial-Part 1.
Kohei Seo, Tetsuya Ishikawa, Yusuke Suzuki, Tatsuya Izdebski, Minako Goto, Tomohiro Oba

J Obstet Gynaecol Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
Hisashi Tanaka, Tomonori Makiguchi, Takehiro Tozuka, Yosuke Kawashima, Tomohiro Oba

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease.
Hideaki Yamakawa, Shintaro Sato, Hiroki Ohta, Kenji Kusano, Rie Kawabe, Tomohiro Oba

Respir Investig· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of Transbronchial Lung Cryobiopsy When Starting Antifibrotic Treatment and Predicting Progressive Fibrosing Interstitial Lung Disease: Descriptive Research.
Makiko Takatsuka, Hideaki Yamakawa, Tamiko Takemura, Shintaro Sato, Hiroki Ohta, Tomohiro Oba

Clin Respir J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051.
Keita Miura, Ou Yamaguchi, Keita Mori, Atsushi Nakamura, Motohiro Tamiya, Tomohiro Oba, Kunihiko Kobayashi

Sci Rep· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Shinsuke Ogusu, Yuhei Harutani, Takehiro Tozuka, Ryota Saito, Junji Koyama, Tomohiro Oba

Cancer Immunol Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of para-carinal air cysts in patients with pleuroparenchymal fibroelastosis: The relationship with pneumomediastinum and pneumothorax.
Hideaki Yamakawa, Shintaro Sato, Hiroki Ohta, Makiko Takatsuka, Kenji Kusano, Tomohiro Oba

Clin Respir J· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis